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Abstract
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias
(NENs), intratherapeutic dosimetry is mandatory for organs at risk (e.g. kidneys) and
tumours. We evaluated commercial dosimetry software (Dosimetry Toolkit) using varying
imaging scenarios, based on planar and/or tomographic data, regarding the differences in
calculated organ/tumour doses and the use for clinical routines. A total of 16 consecutive
patients with NENs treated by PRRT with 177Lu-DOTATATE were retrospectively analysed.
Single-photon emission computed tomography (SPECT)/low-dose computed tomography
(CT) of the thorax and abdomen and whole body (WB) scintigraphy were acquired up to 7
days p.i. (at a maximum of five imaging time points). Different dosimetric scenarios were
evaluated: (1) a multi-SPECT-CT scenario using SPECT/CT only; (2) a planar scenario
using WB scintigraphy only; and (3) a hybrid scenario using WB scintigraphy in combination
with a single SPECT/low-dose CT. Absorbed doses for the kidneys, liver, spleen, lungs,
bladder wall and tumours were calculated and compared for the three different scenarios.
The mean absorbed dose for the kidneys estimated by the multi-SPECT-CT, the planar and
the hybrid scenario was 0.5 ± 0.2 Sv GBq-1, 0.8 ± 0.4 Sv GBq-1 and 0.6 ± 0.3 Sv GBq-1,
respectively. The absorbed dose for the residual organs was estimated higher by the planar
scenario compared to the multi-SPECT-CT or hybrid scenario. The mean absorbed tumour
doses were 2.6 ± 1.5 Gy GBq-1 for the multi-SPECT-CT, 3.1 ± 2.2 Gy GBq-1 for the hybrid
scenario and 5.3 ± 6.3 Gy GBq-1 for the planar scenario. SPECT-based dosimetry methods
determined significantly lower kidney doses than the WB scintigraphy-based method.
Dosimetry based completely on SPECT data is time-consuming and tedious. Approaches
combining SPECT/CT and WB scintigraphy have the potential to ensure compromise
between accuracy and user-friendliness.
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Introduction
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues is an
established treatment option for internal radiation therapy in patients with neuroendocrine
neoplasias (NENs) [1,2]. Currently, PRRT is performed using 177Lu-labelled pharmaceuticals,
because of the physical properties of the radionuclide (e.g. emission types and energy, particle
range in tissue and physical half-life) [3,4] in treatment of NENs [1,5].
In addition to the beneficial effect on tumours, there are also risks associated with PRRT
mostly because of radiation toxicity to tumour-unaffected tissues, especially for kidneys and
red bone marrow. To avoid treatment-related side effects, dosimetry is mandatory for PRRT
for each treatment cycle. For individualised dosimetry, a variety of factors, for example,
tumour size, organ size, uptake and tracer kinetic, should be considered [6–8].
Clinical dosimetry is often performed by evaluating accumulated activity in target regions
using a region of interest (ROI)-based evaluation of planar (2D) whole-body (WB) scintigraphy.
Next, data from ROI analysis were analysed according to medical internal radiation dose (MIRD)
formalism [9,10]. In 2D, the overlapping of regions (e.g. organs) or neglecting additional individ-
ual factors (e.g. organ mass [11]) may lead to incorrect determination of the ROI uptake [12],
resulting in an over- or underestimation of the absorbed dose in the corresponding region. By
using single-photon emission computed tomography (SPECT), the uptake in the ROI is deter-
mined without superimposed structures. The combination with a low-dose computed tomogra-
phy (CT) for morphological mapping and for attenuation correction (CTAC) enables even
further improvement in dosimetry, for example, correction for scattered photons [4,12–20].
However, it should be possible to perform individual dosimetry of PRRT patients in a clini-
cal routine using an integrated patient-friendly workflow. For this reason, this study aimed to
optimise the dosimetry workflow in PRRT examining three different imaging scenarios for
dosimetry: (1) a multi-SPECT-CT scenario using SPECT/low-dose CT only; (2) a planar sce-
nario using WB scintigraphy only; and (3) a hybrid scenario using WB scintigraphy in combi-
nation with a single SPECT/low-dose CT. We compared intra-individually the calculated
organ and tumour doses obtained by the different imaging protocols and the calculation meth-
odologies implemented by a specific software tool certified for clinical dosimetry. Additionally,
we assessed the processing time for the investigator (e.g. physician or physicist) for a single
dosimetric evaluation.
Methods
Patients
Sixteen consecutive patients with NENs (nine male, seven female, aged 65.6 ± 9.7 yr, 51–82 yr)
referred between December 2011 and December 2015 for PRRT with 177Lu-[DOTA0,Tyr3]
octreotate (177Lu-DOTATATE) were retrospectively analysed. The total number of PRRT
cycles was 47 (median = 3, range = 1–4). For the study, we included imaging data of the first
therapy cycle of each patient with their specific physique and accumulation pattern (n = 16).
PRRT was performed in concordance with established clinical guidelines [8,21].
The retrospective analysis (registration number: 77/14, RAD252) was approved by the local
institutional ethics committee (Ethics Committee of the University Hospital Magdeburg). All
patients had provided written informed consent on the evaluation of their data.
Imaging
All examinations were performed using a hybrid SPECT/CT (Discovery NM/CT 670, GE Health-
care, Haifa, Israel). The imaging protocol consisted of planar WB scintigraphy and SPECT/low-
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dose CT of the thorax and abdomen. The protocol included imaging on 5 days between 4 h and
168 h p.i. (post injection), while each patient was examined after 4 h, 24 h and 72 h.
The SPECT gamma camera was equipped with a medium-energy, general propose collima-
tor (MEGP), and all image acquisitions were performed using a single energy window at 208
keV ± 10%. No energy window for scatter correction was applied. Planar WB scintigraphy
(anterior and posterior) was acquired with a matrix of 256 x 1024 and a scan speed of 10 cm
min-1. For each patient, imaging was performed with an individually chosen constant table
high and a fixed detector radius, to realise a minimal distance to the patient contour. For sub-
sequent examinations of the same patient, the initial scan parameters were used. For the esti-
mation of the sensitivity of the gamma camera, a 177Lu-filled syringe (V = 50 mL, A = 196 ± 27
MBq) was measured. The syringe was scanned at every patient WB examination and was
located below the feet of the patient. For SPECT sensitivity, a separate static image of the
syringe was necessary to determine the calibration factor [22]. However, it was also possible to
determine the sensitivity factor in concordance with NEMA procedure [23]. Then the corre-
sponding sensitivity factor can be entered manually.
SPECT data were acquired using automatic body contouring with a total 60 angular views
(30 per detector) at steps of 6˚ (30 s/projections) and a 256 × 256 matrix (pixel size = 2.21 x
2.21 mm, zoom = 1.0). SPECT data were acquired for two bed positions covering the thorax
and abdomen. Low-dose CT imaging was performed with a primary collimation of 16 x 1.25
mm, pitch = 1.375, rotation time = 0.8 s and an X-ray tube voltage of 120 kVp. The X-ray tube
current was 40 mA at the first imaging time point (after 4 h p.i.) and 20 mA for the later four
imaging time points. The CT scans with 40 mA and 20 mA were used for the CTAC of the cor-
responding SPECT data and for the registration of different imaging time points. The CT
scans with 40 mA were further used for morphologic-oriented ROI definition. CT data were
reconstructed with a matrix of 512 x 512 (pixel size = 0.98 x 0.98 mm) and a slice thickness of
3.75 mm by an iterative CT image reconstruction algorithm (adaptive statistical image recon-
struction, ASIR) with an ASIR level of 100% [24].
Dose calculation
Analysis was performed with dedicated dosimetry software (Dosimetry Toolkit—DTK, vendor
GE Healthcare, Haifa, Israel) for examination of pharmacokinetic uptake and calculation of
residence time. Residence time represents the cumulated activity to the organ normalized to
the (total) administered activity to the patient according to the MIRD-concept [9]. The DTK
provided three different evaluation workflows: (1) based on SPECT/CT imaging (multi-
SPECT-CT scenario); (2) based on planar scintigraphy (planar scenario); and (3) based on pla-
nar WB scintigraphy with a supplementary single SPECT/CT examination performed in con-
junction with one of the planar WB scintigraphies (hybrid scenario). Uptake and residence
time were estimated for all patients by each scenario for kidneys, liver, spleen, lungs, bladder
content and at least for one liver tumour. Using DTK, a time-activity curve for each previously
defined ROI was estimated and fitted automatically by a mono-exponential function for the
calculation of residence time. Other analytic fit functions (e.g. bi-exponential function) were
not implemented. A final report of the DTK is shown in Fig 1. Using the hybrid scenario, the
time-activity curve for each ROI, estimated from sequential planar scintigraphies, was scaled
by the activity inside a corresponding volume of interest (VOI) estimated from a single SPECT
[22]. Personalized organ dose calculations were performed using OLINDA/EXM software [25]
with residence times calculated by DTK.
All dose values calculated by OLINDA/EXM were corrected for gender and adjusted indi-
vidually for organ/patient weight. Organ masses were calculated from organ volume
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individually estimated from CT data by using standardized organ densities [26]. Furthermore,
the absorbed doses of tumour lesions in the liver were calculated by the density sphere model
implemented in OLINDA/EXM [20,27,28] using the volume estimated from CT volumetry
and considering a tumour lesion density equal to the liver. All tumour doses were corrected
for partial volume effect.
Additionally, CT exposure was analysed by evaluating the dose length product (DLP) docu-
mented by the CT. The effective (E) dose for the low-dose CT imaging procedure was calcu-
lated by the software CT-Expo [29].
Multi-SPECT-CT scenario
This scenario is based solely on SPECT/CT data. Image reconstruction was performed by iterative
ordered-subset expectation maximisation algorithm (OSEM, 5 iterations, 10 subsets, HANN fil-
ter-function with 0.9 cycles/cm) with CTAC. The registration of all scans to one reference scan
(the latest SPECT/CT) and the subsequent organ registration were performed by the DTK.
The segmentation of the VOIs (e.g. for organs and tumours) was performed by automatic,
semi-automatic and manual DTK tools using CT or SPECT data. VOI segmentation started
with the first SPECT/CT scan (4h p.i.). After defining VOIs for the first SPECT/CT, the VOIs
were copied automatically to the residual SPECT/CTs. The VOIs were adjusted for each time
point manually if appropriate. Representative VOIs are shown in Fig 2A.
Fig 1. A representative final report of the Dosimetry Toolkit. (A) Illustration of the serial images of a patient with all regions of interest 4 h, 24 h, 48 h, 72 h
and 168h p.i. (B) Normalised time-activity curves for all regions of interest. (C) Calculated residence times of all regions of interest.
https://doi.org/10.1371/journal.pone.0187570.g001
Software-assisted dosimetry in PRRT
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Planar scenario
Geometric mean images (square root of the product of the counts in the anterior and posterior
projections) were automatically calculated from the WB scintigraphies for each time point.
The resulting images were co-registered to the first imaging time point (4 h p.i.).
ROIs for body contour and calibration standard (syringe) were automatically defined by
the DTK. ROIs for organs and tumours were defined manually with ROI drawing tools for the
first imaging time point. After confirming all ROIs, they were automatically copied to the geo-
metric mean images of later time points. Representative ROIs are shown in Fig 2B. Back-
ground correction for the count rate was performed for each organ ROI. The corresponding
background ROI was defined automatically for each time point next to the organ ROI (Fig
2B). The Background correction for the counts estimated for an organ ROI was applied by sub-
tracting the weighted background counts. Weighting was performed by a factor (wf)
Fig 2. ROI/VOI comparison of all three imaging scenarios 24 h p.i. of the same patient. The delineations of lungs, liver, kidneys, spleen, bladder and
tumour (white, in the liver) are shown. (A) 2D presentation (summed coronal slice) of the 3D VOIs of the multi-SPECT-CT scenario. (B) Geometric mean
image of the planar scenario with all ROIs. The small elongated delineations (*) next to the ROIs were used for background correction. (C) Geometric mean
image of the WB scintigraphies with SPECT/CT based VOIs (hybrid scenario). Here, overlapping regions of interest were automatically removed (#) and
corrected.
https://doi.org/10.1371/journal.pone.0187570.g002
Software-assisted dosimetry in PRRT
PLOS ONE | https://doi.org/10.1371/journal.pone.0187570 November 6, 2017 5 / 14
respecting the organ thickness [30].
wf ¼ 1  
dorgan
dbody
ð1Þ
The extension of the organ (dorgan) and the body (dbody) in the anterior–posterior direction
was previously estimated from CT scans.
Hybrid scenario
The hybrid scenario combined a series of WB scintigraphies with a single SPECT/CT acquired in
a timely manner corresponding to one of the WB scintigraphies. The pre-processing of the scin-
tigraphies is identical to the planar scenario. Furthermore, the SPECT data were reconstructed
and a summed coronal slice, representing the reference image, was calculated. The co-registered
series of geometric mean WB images were automatically registered to the summed slice.
Furthermore, VOIs (e.g. organs and tumours) were defined by using SPECT/CT data that
were acquired nominally 24 h p.i. Finally, the determined VOIs were projected by the DTK to
registered geometric mean images. Volumes (or parts of volumes) overlapping in the 2D pro-
jection were not considered by DTK for analysis of the geometric mean images (Fig 2C). In
these cases, organ activity was corrected for the activity in the removed volume by using the
mean activity concentration in the residual volume (VOI) as a surrogate for substitution.
Inter-observer variability
The influence of observers on ROI definition was examined and inter-observer variability was
tested for three independent observers (C.H., H.W. and D.K) defining the kidney ROIs for all
patients. All observers were experienced in nuclear medical imaging and clinical dosimetry
(4–20 years). The influence of the observer on kidney dosimetry was tested for WB scintigra-
phy data and for the SPECT/CT data (24 h p.i.). Furthermore, the time required for ROI/VOI
delineation was determined.
Statistics
The R software package (version 3.2.0, R Foundation for Statistical Computing, Vienna, Austria)
was used for statistical evaluations. Descriptive parameters were expressed as mean ± standard
deviation (SD), median, interquartile range (IQR; 25th/75th percentiles) and range. The organ and
tumour doses per injected activity calculated by the different scenarios were tested for differences
using the Friedman test and Wilcoxon signed-rank test, if applicable. The multi-SPECT-CT sce-
nario represented the standard of truth for this study. Inter-observer variability of the observer in
drawing kidneys ROI was examined by Kendall’s coefficient of concordance wt. All tests were per-
formed two-sided, and statistical significance was assumed at a p-value of< 0.05.
Results
The mean administered activity of 177Lu-Dotatate was A = 7.2 ± 0.4 GBq. The mean weighting
factors (wf) used for the planar scenario were: wfKidneys = 0.82 ± 0.06, wfLiver = 0.52 ± 0.23,
wfSpleen = 0.80 ± 0.10, wfLung = 0.44 ± 0.17, wfBladder = 0.77 ± 0.12 and wfTumour = 0.92 ± 0.04.
A detailed summary of the determined organ masses and organ residence times for dosime-
try are presented in Table 1 and Table 2. The dose per injected activity (DpA) for each organ is
shown in Table 3.
There were no significant differences in residence times between the examined three imag-
ing scenarios for the liver (p = 0.7788) and the bladder content (p = 0.2574). The residence
Software-assisted dosimetry in PRRT
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times of the kidneys (p = 0.0023), spleen (p = 0.0013) and lung (p< 0.0001) differed signifi-
cantly between the three imaging scenarios.
Dose to organs
The mean absorbed doses for both kidneys were 3.5 ± 1.4 Sv for the multi-SPECT-CT scenario,
4.3 ± 2.2 Sv for the hybrid scenario and 5.5 ± 3.3 Sv for the planar scenario. The organ dose
estimated by the scenarios was significantly different (p = 0.0023). The median DpA of the kid-
neys, estimated by the hybrid and planar scenario, was compared to the multi-SPECT-CT sce-
nario and increased by a factor of 1.2 (p = 0.0052) and 1.6 (p = 0.0013), respectively.
The mean absorbed dose for the liver was 4.8 ± 4.4 Sv for the multi-SPECT-CT scenario,
5.0 ± 4.5 Sv for the hybrid scenario and 4.5 ± 3.8 Sv for the planar scenario. The organ dose cal-
culated by the three different imaging scenarios was not significantly different (p = 0.7788).
Table 1. Patient whole body (WB) weight and determined organ masses. The individual masses estimated with low-dose CT volumetry were used for
weight adjustments in OLINDA/EXM software.
WB (g) Kidneys (g) Liver (g) Spleen (g) Lungs (g)
Female
mean ± SD 69,000 ± 12,383 400 ± 73 3,338 ± 3,808 461 ± 543 461 ± 128
50th (25th/75th) 76,000 (57,500/76,500) 407 (354/421) 1,505 (1,442/3,058) 199 (194/395) 619 (553/717)
range 54,000–85,000 307–535 1,092–11,770 170–1,578 458–832
Male
mean ± SD 84,670 ± 13,077 611 ± 104 2,644 ± 797 267 ± 141 829 ± 124
50th (25th/75th) 90,000 (75,000/94,000) 649 (522/652) 2,777 (2,035/2,968) 233 (213/244) 793 (725/910)
range 66,000–101,000 475–812 1,558–3,922 127–598 681–1,017
Note: Organ mass was calculated by using a standardized tissue density for each organ (kidney = 1.05 g mL-1, liver = 1.06 g mL-1, spleen = 1.06 g mL-1,
lungs = 0.26 g mL-1) [26].
https://doi.org/10.1371/journal.pone.0187570.t001
Table 2. Residence times for the first therapy cycle (n = 16 patients) estimated by DTK using different imaging scenarios.
Kidneys (h) Liver (h) Spleen (h) Lungs (h) Bladder Content (h)
Multi-SPECT-CT
mean ± SD 2.7 ± 0.8 29.1 ± 43.3 3.3 ± 4.7 0.6 ± 0.5 0.9 ± 0.5
50th (25th/75th) 2.5 (2.4/3.1) 10.6 (5.4/32.7) 2.4 (1.3/3.1) 0.5 (0.3/0.7) 0.7 (0.5/1.3)
range 1.3–4.3 1.4–165.4 0.7–19.9 0.1–2.3 0.3–1.6
Hybrid
mean ± SD 3.3 ± 1.4 29.4 ± 39.3 3.7 ± 4.3 0.7 ± 0.5 0.7 ± 1.2
50th (25th/75th) 3.1 (2.40/3.9) 9.0 (6.0/41.2) 2.8 (1.8/3.5) 0.6 (0.3/0.9) 0.3 (0.2/0.4)
range 1.3–6.2 1.1–147.0 0.6–19.3 0.1–2.0 0.1–5.0
pa 0.0034 n.s.c 0.0355 0.5282 n.s.c
Planar
mean ± SD 4.1 ± 1.6 23.4 ± 25.0 4.2 ± 2.6 3.0 ± 1.1 1.0 ± 0.8
50th (25th/75th) 4.3 (3.0/5.3) 9.5 (5.4/46.1) 3.5 (2.9/4.7) 2.9 (2.3/3.7) 0.8 (0.5/1.4)
range 1.3–7.2 2.4–66.8 1.3–12.4 1.0–5.3 0.2–3.1
pb 0.0017 n.s.c 0.0115 < 0.0001 n.s.c
aSignificance of differences between the multi-SPECT-CT and hybrid scenario (Wilcoxon signed-rank test)
bSignificance of differences between the multi-SPECT-CT and planar scenario (Wilcoxon signed-rank test)
cn.s. (not significant) differences between the three groups (Friedman test)
https://doi.org/10.1371/journal.pone.0187570.t002
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The calculations for the spleen revealed a mean absorbed dose of 5.9 ± 3.1 Sv for the
multi-SPECT-CT scenario, 7.0 ± 4.1 Sv for the hybrid scenario and 10.4 ± 6.5 Sv for the planar
scenario. The dose estimated by the three imaging scenarios was significantly different
(p = 0.0013). The median DpA of the spleen was for the hybrid scenario, which increased by a
factor of 1.3 (p = 0.0256) and for the planar scenario by a factor of 1.6 (p = 0.0020) compared
to the multi-SPECT-CT scenario.
For the lungs, mean absorbed doses were 0.6 ± 0.4 Sv for the multi-SPECT-CT scenario,
1.0 ± 1.3 Sv for the hybrid scenario and 2.6 ± 1.1 Sv for the planar scenario. Compared to the
multi-SPECT-CT scenario, the median DpA of the hybrid scenario was not significantly differ-
ent (p = 0.4332), but the DpA was significantly higher for the planar scenario with a factor of
6.7 (p< 0.0001).
The mean absorbed dose for the bladder wall was 1.5 ± 0.8 Sv for the multi-SPECT-CT sce-
nario, 1.3 ± 2.5 Sv for the hybrid scenario and 1.8 ± 1.4 Sv for the planar scenario. The bladder
content volume varied considerably between patients, 318 ± 238 mL (108–954 mL). There
were no significant differences between the imaging scenarios, p = 0.2574.
Dose to tumours
Liver tumour lesions (n = 23) were evaluated for each scenario. The tumour masses were
54 ± 87 g (median = 20 g, range = 3–403 g). The details of the tumour doses are shown in
Table 4. The mean absorbed tumour doses were 22.1 ± 12.9 Gy for the multi-SPECT-CT sce-
nario, 25.3 ± 17.4 Gy for the hybrid scenario and 45.3 ± 56.8 Gy for the planar scenario. The
difference between the scenarios was not significant (p = 0.1199).
Inter-observer variability
Definition of 3D kidney VOIs showed a very good inter-observer agreement with respect to
the extracted counts, wt = 0.937 (p = 0.0003). A good inter-observer agreement was estimated
for the definition of 2D kidney ROIs using planar images, wt = 0.634 (p = 0.0018). The mean
Table 3. Dose per injected activity for the first therapy cycle (n = 16 patients), with respect to the different evaluation scenarios.
Kidneys (Sv GBq-1) Liver (Sv GBq-1) Spleen (Sv GBq-1) Lungs (Sv GBq-1) Bladder Wall (Sv GBq-1)
Multi-SPECT-CT
mean ± SD 0.477 ± 0.184 0.663 ± 0.618 0.816 ± 0.406 0.081 ± 0.062 0.199 ± 0.110
50th (25th/75th) 0.413 (0.325/0.593) 0.375 (0.278/0.935) 0.697 (0.488/1.150) 0.055 (0.039/0.106) 0.173 (0.102/0.301)
range 0.272–0.896 0.080–2.075 0.293–1.584 0.013–0.202 0.061–0.383
Hybrid
mean ± SD 0.588 ± 0.297 0.696 ± 0.624 0.962 ± 0.530 0.130 ± 0.173 0.177 ± 0.335
50th (25th/75th) 0.503 (0.353/0.819) 0.403 (0.264/1.031) 0.930 (0.516/1.090) 0.086 (0.037/0.139) 0.088 (0.046/0.102)
range 0.295–1.298 0.067–2.332 0.257–2.089 0.017–0.744 0.029–1.362
pa 0.0052 n.s.c 0.0256 0.4332 n.s.c
Planar
mean ± SD 0.757 ± 0.433 0.627 ± 0.535 1.429 ± 0.864 0.362 ± 0.141 0.241 ± 0.177
50th (25th/75th) 0.647 (0.524/0.908) 0.441 (0.288/0.667) 1.136 (0.728/1.906) 0.367 (0.260/0.422) 0.176 (0.136/0.285)
range 0.248–1.823 0.143–1.831 0.576–3.623 0.148–0.698 0.054–0.647
pb 0.0013 n.s.c 0.0020 < 0.0001 n.s.c
aSignificance of differences between the multi-SPECT-CT and hybrid scenario (Wilcoxon signed-rank test)
bSignificance of differences between the multi-SPECT-CT and planar scenario (Wilcoxon signed-rank test)
cn.s. (not significant) differences between the three groups (Friedman test)
https://doi.org/10.1371/journal.pone.0187570.t003
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time for drawing kidneys in planar WB scintigraphy was 20 ± 4 s, 15–32 s (C.H.: 24 ± 3 s, D.K.:
18 ± 2 s, and H.W.: 19 ± 2 s). The mean time needed for drawing kidneys in the SPECT/CT
data was 151 ± 44 s, 77–316 s (C.H.: 123 ± 33 s, D.K.: 134 ± 13 s, and H.W.: 195 ± 41 s). The
time for defining the ROI in WB scintigraphy data was significantly smaller compared to
defining the VOI in the SPECT/CT data (p< 0.0001).
CT dose exposure
The effective dose for a single low-dose-CT examination (scan length of 80 cm, thorax and
abdomen) was E = 2.6 mSv (male) and 3.2 mSv (female) for a tube current of I = 40 mA
(DLP = 172.6 mGy cm) and E = 1.2 mSv (male) and 1.6 mSv (female) for I = 20 mA (DLP =
86.3 mGy cm). A single PRRT cycle yielded an effective dose from CT exposure of E = 7.4 mSv
(male) and 9.6 mSv (female) for the multi-SPECT-CT scenario and a CT exposure of E = 2.6
mSv (male) and 3.2 mSv (female) for the hybrid scenario.
Discussion
In this study, we used two commercially available software tools (DTK and OLINDA/EXM)
for semi-automatic evaluation of organ doses in PRRT with 177Lu-DOTATATE. We compared
dose values for different organs and for tumours estimated by three different scenarios based
on SPECT/low-dose CT, planar WB imaging and a hybrid protocol with planar WB imaging
and SPECT/low-dose CT imaging. Each scenario differed in terms of accuracy, exposure from
additional CT imaging and processing time.
The determined mean DpA of 0.8 ± 0.4 Sv GBq-1 for the kidneys per treatment cycle esti-
mated by the planar scenario was comparable to results of other studies using planar WB
approaches (range: 0.6–1.2 Gy GBq-1) [12,16,19,28,31]. The kidney doses estimated by SPECT/
CT-based methods were lower compared to previous results. Garkavij et al. [12] used a hybrid
approach in their work, in which planar WB data were scaled by uptake values from SPECT
data. They reported an average DpA of 0.8 ± 0.2 Gy GBq-1 (our data: 0.6 ± 0.3 Sv GBq-1).
Authors using multi-SPECT/CT methodology reported a mean kidney dose of 2.6–9.1 Gy per
treatment cycle [13,17,18]. Here, our results are comparable to published studies. The DpA
calculated for liver by the planar scenario (0.6 ± 0.5 Sv GBq-1) exceeds the published values by
0.2 to 0.3 Gy GBq-1 [28,31]. In contrast, the mean dose estimated by the multi-SPECT-CT sce-
nario converges with the range of published data of 1.9 to 4.5 Gy [13,17,18]. Both the calcu-
lated spleen doses for the planar and the multi-SPECT-CT scenario are in good agreement
with the available literature [13,17,18,28,31]. Since the lung and bladder wall in PRRT with
177Lu-DOTATATE are not considered as organs at high risk, no corresponding reference val-
ues were reported by other authors.
Table 4. Dose per injected activity (DpA) and absorbed tumour doses of n = 23 liver tumour lesions of 16 patients for the first therapy cycle.
Multi-SPECT-CT Hybrid Planar p
DpA (Gy GBq-1)
mean ± SD 2.58 ± 1.47 3.09 ± 2.16 5.32 ± 6.26
50th (25th/75th) 2.71 (1.26/3.65) 2.70 (1.34/3.74) 3.13 (2.43/4.65) 0.1199
Range 0.16–5.35 0.20–7.89 0.18–25.30
Dose (Gy)
mean ± SD 22.08 ± 12.91 25.27 ± 17.37 45.30 ± 56.75
50th (25th/75th) 21.70 (11.40/29.75) 24.30 (11.65/29.15) 26.50 (19.75/43.55) 0.1835
Range 1.40–47.60 1.90–59.00 1.60–259.10
https://doi.org/10.1371/journal.pone.0187570.t004
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The multi-SPECT-CT scenario provides probably the most accurate data (e.g. for residence
times) compared to the planar scenario due to the definition of non-overlapping 3D VOIs by
using CT information [32] and the evaluation of CTAC corrected SPECT data [33]. However,
the multi-SPECT-CT scenario was highly time-consuming because of the pre-processing of
the raw data (reconstruction of SPECT data and co-registration) and the elaborated VOI defi-
nition. In addition, the patient accumulated an additional CT exposure from each hybrid
SPECT/CT scan. This exposure was significantly smaller for the hybrid scenario using a single
hybrid SPECT/CT and was absent for the planar scenario. Using the multi-SPECT-CT sce-
nario for dosimetry, the median DpAs were estimated to be significantly lower for organs (e.g.
organs at risk) compared to the planar or hybrid imaging approach. The planar scenario was
the fastest and easiest dosimetry scenario due to the simple pre-processing and ROI drawing.
The calculated DpAs from the planar scenario were significantly higher for the kidneys, spleen,
and lungs and slightly but not significantly increased for the liver and bladder wall compared
to the multi-SPECT-CT scenario. The overestimation of the organ doses of the planar 2D
imaging scenario compared to the SPECT/CT imaging scenario was due to increased residence
times caused by the overlapping segmentation of organ ROIs [32], the non-attenuation cor-
rected data used for dosimetry [33] and the weighting factor for organ thickness for the correc-
tion of the count-rate. The lack of consideration of photon attenuation in planar-only imaging
methods was probably an important source of error compared to CTAC SPECT-based meth-
ods [22]. Especially, in the thoracic region, the lack of attenuation correction led to an overesti-
mation of the lung dose [34]. Furthermore, the high systematic overestimation of the lung
dose with the planar scenario by a factor of 6.7 may have been due to the weighting factor of
the lungs (wfLung = 0.44 ± 0.12). As mentioned, this factor was obtained by the ratio of organ
thickness to body thickness (Eq 1) and was used to correct the count-rate and therefore the res-
idence time. Since the thickness of the lungs varied widely from the apex to the base and only
one weighting factor for thickness per organ can be used in the DTK, it is likely that a reduc-
tion of the weighting factor for organ thickness would provide results that are more represen-
tative. Compared to the lungs, the kidneys and the spleen have a relatively simple geometric
shape, so these weighting factors are probably less error-prone. Unfortunately, an ROI-based
background correction to another ROI or a smaller ROI within the target region of the planar
data is not provided by the DTK. Such a correction could improve the results of the planar
methodology [12]. Furthermore, a correction for the individual organ masses was applied.
Using the standard organ masses of OLINDA/EXM, dose calculation can be further distorted
resulting in an overestimation of organ dose in our cohort.
In the hybrid scenario, organ VOIs were drawn overlap-free in SPECT or CT data before
they were projected onto the planar WB data. A correction for overlapping compartments was
performed automatically. Because of the pre-processing and VOI/ROI definition, the time
required for the hybrid scenario was less than the time of the multi-SPECT-CT scenario but
increased compared to the planar scenario. The calculated DpA did not significantly differ
from the multi-SPECT-CT scenario except for the kidneys and the spleen. The difference in
results between the multi-SPECT-CT and hybrid scenario could arise from the automatic
removal of overlapping ROIs (e.g. right kidney and liver). For the extrapolation of overlapping
regions, a uniformly distributed activity in the VOIs was assumed [35]. Inhomogeneous
uptake in organs or tumour lesions in the organs might compromise the extrapolation and
thus the calculation of the residence time. Another limitation, due to our imaging protocol,
occurred when the SPECT data were co-registered to the planar WBs. Here, different patient
positioning (e.g. SPECT imaged with arms stretched upwards and WB imaged with arms next
to the body) may have led to an internal shift of organs and tumours.
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Tumour dosimetry was focused on the liver, since all enrolled patients had NENs with
liver-dominant metastases. The dose calculations for the multi-SPECT-CT and hybrid sce-
nario revealed a median DpA of 2.7 Gy GBq-1 (multi-SPECT-CT scenario: 22 ± 13 Gy, hybrid
scenario: 25 ± 17 Gy). For the planar scenario, a median DpA of 3.1 Gy GBq-1 (or 45 ± 57 Gy)
was estimated. Other authors reported a comparable tumour dose based on three SPECT/CTs
per treatment cycle (21.4 ± 9.7 Gy [17] and 20 Gy [20] with a range of 10–170 Gy [20]). The
tumour dose (69 ± 33 Gy) by Gupta et al. [28] determined from planar WB data was larger
compared to our planar tumour dose. However, because of heterogeneity in tumours (e.g.
somatostatin receptor density and vascularisation) the doses are not necessarily comparable.
Furthermore, we used the density sphere model implemented in OLINDA/EXM for tumour
dose calculation. This model was based on assumptions (e.g. spherical tumour volume and a
homogeneous activity distribution), which can result in erroneous tumour dose calculation.
Furthermore, cross-radiation has not been considered [25]. Particularly large tumours proba-
bly do not fit the spherical shape and small tumours are compromised by a partial volume
effect.
The basic clinical impact of our results is the demonstrated difference in organ doses esti-
mated by various methodologies for organs at risk (e.g. kidneys) in PRRT. Depending on the
imaging scenario used for dosimetry, the patients accumulate significantly different kidney
doses, which, in turn, affect the number of possible treatment cycles. Patients evaluated with
the planar scenario would exceed the tolerance dose of the kidneys (23 Gy [36]) after an aver-
age of eight treatment cycles, whilst the accumulated dose calculated by the multi-SPECT-CT
scenario is only two-thirds of the reported tolerance. Even the tolerance dose for the kidneys
is under discussion according to MIRD 26 [22], so it is either 23 Gy or 27 Gy. Furthermore,
higher tolerance doses for the kidneys were proposed (28 Gy and 40 Gy) [22]. Naturally, addi-
tional treatment cycles are determined by further parameters (e.g. absorbed dose to the bone
marrow). However, with respect to this dose, Sandstro¨m et al. [18] demonstrated in their work
with 200 patients that the kidneys were the organ at risk in about 98% of all cases. We deter-
mined the dose to the red bone marrow by measuring several blood samples with a calibrated
NaI-scintillation detector [6]. Because no imaging approach was used for analysis, the data
were not published by this study.
Obviously, our dosimetric comparison is restricted to the software provided by the vendor,
GE Healthcare, and therefore is subject to the limitations of this particular software package.
For example, it is not possible to perform bi-exponential fits for the estimation of the residence
time. Even though this would be very useful, especially for the evaluation of specific kinetics
(e.g. kidney). This is a limitation that was also reported for actual dosimetric studies (study
from Uppsala) [22].
Furthermore, the dead time effects for 177Lu-DOTATATE dosimetry are small and a cor-
rection was not applied since only the first imaging time point (4 h p.i.) may be effected [22]
and dose calculations were performed over 7 days. Nevertheless, the software-assisted work-
flows simplified and improved essential steps in the internal dosimetry due to automated pro-
cessing, and the use of specific image editing and segmentation tools (e.g. with correction for
overlapping organs). Moreover, a good agreement was observed for organ dosimetry (e.g. kid-
neys) by using the software toolbox independent of the user’s experience. The CT-based seg-
mentation resulted in an almost perfect agreement of the organ definitions with a similar renal
dose determined by the different observers.
The usage of scatter corrections for 177Lu imaging is the subject of current discussions.
Depending on the collimator, the number of scatter windows, and the width of energy win-
dows, Nijs et al. [37] have shown that the reconstructed scatter corrected counts either under-
or overestimated the activity in a lesion (VOI). Our imaging protocol was in accordance with
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the current MIRD 26 [22] published energy window settings of the study of Uppsala in which
no scatter correction was applied.
Conclusion
SPECT/CT-based dosimetry methods determined significantly lower organ doses compared
to the planar scintigraphy method, which was possibly due to the benefit of a CTAC and
overlap-free uptake calculation. However, dosimetry based completely on SPECT data is time-
consuming and tedious. Hybrid imaging approaches combining SPECT/CT and planar delin-
eation provide a compromise between accuracy and user-friendliness.
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